- Featured Product
- KD/KO Validated
SLC35F2 Polyklonaler Antikörper
SLC35F2 Polyklonal Antikörper für WB, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus
Anwendung
WB, IP, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 25526-1-AP
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in WB | A549-Zellen, Maushirngewebe |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| KD/KO | See 1 publications below |
| WB | See 5 publications below |
| IP | See 1 publications below |
Produktinformation
25526-1-AP bindet in WB, IP, ELISA SLC35F2 und zeigt Reaktivität mit human, Maus
| Getestete Reaktivität | human, Maus |
| In Publikationen genannte Reaktivität | human |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | SLC35F2 fusion protein Ag20901 |
| Vollständiger Name | solute carrier family 35, member F2 |
| Berechnetes Molekulargewicht | 374 aa, 41 kDa |
| Beobachtetes Molekulargewicht | 41-50 kDa |
| GenBank-Zugangsnummer | BC039195 |
| Gene symbol | SLC35F2 |
| Gene ID (NCBI) | 54733 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
SLC35F2, also named as Solute carrier family 35 member F2, is a 374 amino acid protein, which belongs to the SLC35F solute transporter family. SLC35F2 as a Multi-pass membrane protein is a putative solute transporter. SLC35F2 is highly homologous to the lung squamous cell cancer-related gene, LSCC3, which is highly expressed in lung squamous cell tumour tissues. However, the clinical implication of the SLC35F2 gene in tumour development and progression remains unclear.
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| WB protocol for SLC35F2 antibody 25526-1-AP | Protokoll herunterladen |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
Theranostics USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2 | ||
Mol Cancer Res Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. | ||
Biochem Biophys Res Commun βTrCP1 promotes SLC35F2 protein ubiquitination and inhibits cancer progression in HeLa cells | ||
Onco Targets Ther Knockdown of SLC35F2 Inhibits the Proliferation and Metastasis of Bladder Cancer Cells.
| ||
Biochim Biophys Acta Gen Subj E3 ubiquitin ligase APC/CCdh1 regulates SLC35F2 protein turnover and inhibits cancer progression in HeLa cells |

